Abstract
A human epidermal growth factor receptor 2 (HER2)-specific nanobody called 2Rs15d, containing a His3LysHis6 segment at the C-terminus, was recombinantly produced. Subsequent site-selective acylation on the C-terminally activated lysine residue allowed installation of the cytotoxin monomethyl auristatin E-functionalized cathepsin B-sensitive payload to provide a highly homogenous nanobody–drug conjugate (NBC), which demonstrated high potency and selectivity for HER2-positive breast cancer models.
Original language | English |
---|---|
Article number | 391 |
Journal | Molecules |
Volume | 30 |
Issue number | 2 |
Number of pages | 12 |
ISSN | 1420-3049 |
DOIs | |
Publication status | Published - 2025 |
Keywords
- Breast cancer
- Targeted treatment
- Nanobody
- Site-selective conjugation